ANEBULO PHARMACEUTICALS, INC. Basic Shares Outstanding (Weighted Average)
ANEBULO PHARMACEUTICALS, INC. (ANEB) reported Basic Shares Outstanding (Weighted Average) of 41.08 million shares for the 3-month period ending 2025-12-31, per its 10-Q filed 2026-02-12.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-02-12
- ANEBULO PHARMACEUTICALS, INC. weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was 41.08M shares, a 49.86% increase year-over-year.
- ANEBULO PHARMACEUTICALS, INC. weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 41.08M shares, a 58.43% increase year-over-year.
- ANEBULO PHARMACEUTICALS, INC. weighted average number of shares outstanding, basic for the quarter ending 2025-06-30 was 41.06M shares, a 58.32% increase year-over-year.
- ANEBULO PHARMACEUTICALS, INC. weighted average number of shares outstanding, basic for the quarter ending 2025-03-31 was 41.08M shares, a 58.43% increase year-over-year.
- ANEBULO PHARMACEUTICALS, INC. weighted average number of shares outstanding, basic for fiscal 2025 was 33.82M shares, a 30.97% increase from fiscal 2024.
- ANEBULO PHARMACEUTICALS, INC. weighted average number of shares outstanding, basic for fiscal 2024 was 25.82M shares, a 2.98% increase from fiscal 2023.
- ANEBULO PHARMACEUTICALS, INC. weighted average number of shares outstanding, basic for fiscal 2023 was 25.07M shares, a 7.41% increase from fiscal 2022.
- ANEBULO PHARMACEUTICALS, INC. weighted average number of shares outstanding, basic for fiscal 2022 was 23.34M shares, a 71.49% increase from fiscal 2021.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 12 month |
|---|---|---|---|---|
| 2025-12-31 | 41.08M shares 10-Q · filed 2026-02-12 | 41.08M shares 10-Q · filed 2026-02-12 | 41.08M shares derived: average of 3 quarters · filed 2026-02-12 | 41.08M shares derived: average of 4 quarters · filed 2026-02-12 |
| 2025-09-30 | 41.08M shares 10-Q · filed 2025-11-13 | 41.07M shares derived: average of 2 quarters · filed 2025-11-13 | 41.08M shares derived: average of 3 quarters · filed 2025-11-13 | 37.66M shares derived: average of 4 quarters · filed 2026-02-12 |
| 2025-06-30 | 41.06M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-29 | 41.07M shares derived: average of 2 quarters · filed 2025-09-29 | 36.52M shares derived: average of 3 quarters · filed 2026-02-12 | 33.82M shares 10-K · filed 2025-09-29 |
| 2025-03-31 | 41.08M shares 10-Q · filed 2025-05-13 | 34.25M shares derived: average of 2 quarters · filed 2026-02-12 | 31.41M shares 10-Q · filed 2025-05-13 | 30.09M shares derived: average of 4 quarters · filed 2026-02-12 |
| 2024-12-31 | 27.42M shares 10-Q · filed 2026-02-12 | 26.67M shares 10-Q · filed 2026-02-12 | 26.43M shares derived: average of 3 quarters · filed 2026-02-12 | 26.30M shares derived: average of 4 quarters · filed 2026-02-12 |
| 2024-09-30 | 25.93M shares 10-Q · filed 2025-11-13 | 25.93M shares derived: average of 2 quarters · filed 2025-11-13 | 25.93M shares derived: average of 3 quarters · filed 2025-11-13 | 25.90M shares derived: average of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | 25.93M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-29 | 25.93M shares derived: average of 2 quarters · filed 2025-09-29 | 25.89M shares derived: average of 3 quarters · filed 2025-09-29 | 25.82M shares 10-K · filed 2025-09-29 |
| 2024-03-31 | 25.93M shares 10-Q · filed 2025-05-13 | 25.86M shares derived: average of 2 quarters · filed 2025-05-13 | 25.78M shares 10-Q · filed 2025-05-13 | 25.75M shares derived: average of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | 25.79M shares 10-Q · filed 2025-02-14 | 25.71M shares 10-Q · filed 2025-02-14 | 25.68M shares derived: average of 3 quarters · filed 2025-02-14 | 25.67M shares derived: average of 4 quarters · filed 2025-02-14 |
| 2023-09-30 | 25.63M shares 10-Q · filed 2024-11-13 | 25.63M shares derived: average of 2 quarters · filed 2024-11-13 | 25.63M shares derived: average of 3 quarters · filed 2024-11-13 | 25.63M shares derived: average of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | 25.63M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-25 | 25.63M shares derived: average of 2 quarters · filed 2024-09-25 | 25.63M shares derived: average of 3 quarters · filed 2024-09-25 | 25.07M shares 10-K · filed 2024-09-25 |
| 2023-03-31 | 25.63M shares 10-Q · filed 2024-05-15 | 25.63M shares derived: average of 2 quarters · filed 2024-05-15 | 24.89M shares 10-Q · filed 2024-05-15 | 24.51M shares derived: average of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | 25.63M shares 10-Q · filed 2024-02-13 | 24.52M shares 10-Q · filed 2024-02-13 | 24.13M shares derived: average of 3 quarters · filed 2024-02-13 | 23.93M shares derived: average of 4 quarters · filed 2024-02-13 |
| 2022-09-30 | 23.42M shares 10-Q · filed 2023-11-14 | 23.38M shares derived: average of 2 quarters · filed 2023-11-14 | 23.37M shares derived: average of 3 quarters · filed 2023-11-14 | 23.36M shares derived: average of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | 23.34M shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-09-22 | 23.34M shares derived: average of 2 quarters · filed 2023-09-22 | 23.34M shares derived: average of 3 quarters · filed 2023-09-22 | 23.34M shares 10-K · filed 2023-09-22 |
| 2022-03-31 | 23.34M shares 10-Q · filed 2023-05-11 | 23.34M shares derived: average of 2 quarters · filed 2023-05-11 | 23.34M shares 10-Q · filed 2023-05-11 | |
| 2021-12-31 | 23.34M shares 10-Q · filed 2023-02-10 | 23.34M shares 10-Q · filed 2023-02-10 | ||
| 2021-09-30 | 23.34M shares 10-Q · filed 2022-11-10 | |||
| 2021-06-30 | 13.61M shares 10-K · filed 2022-09-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |